The CT-based attenuation index of peri-bowel adipose tissue can predict disease progression in inflammatory bowel disease patients - Scorecard - MDSpire
Advertisement
The CT-based attenuation index of peri-bowel adipose tissue can predict disease progression in inflammatory bowel disease patients
Clinical Scorecard: CT-derived attenuation index of peribowel fat tissue as a predictor of disease advancement in patients with inflammatory bowel disease
At a Glance
Category
Detail
Condition
Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD)
Key Mechanisms
Chronic immune-mediated inflammation causing bowel wall inflammation and increased permeability leading to peri-bowel fat inflammation measurable by CT-derived fat attenuation index (FAI)
Target Population
Adult patients with confirmed diagnosis of IBD (UC or CD) undergoing abdominal CT and endoscopy
Care Setting
Hospital or clinical setting with access to abdominal CT imaging and endoscopic evaluation
Key Highlights
Peri-bowel fat attenuation index (FAI) from conventional abdominal CT quantifies inflammation-induced changes in peri-bowel fat.
FAI may predict disease progression independently of traditional noninvasive biomarkers like CRP, ESR, and fecal calprotectin.
Disease progression defined by clinical events including surgery, hospitalization, steroid initiation, or medication escalation.
Guideline-Based Recommendations
Diagnosis
Confirm IBD diagnosis based on clinical, endoscopic, imaging, and histological criteria.
Use abdominal CT within 1 week of endoscopy to assess peri-bowel fat inflammation via FAI.
Management
Apply treat-to-target approach focusing on early control of inflammation to limit disease progression.
Select initial therapy based on risk stratification including FAI measurement to identify high-risk patients.
Monitoring & Follow-up
Monitor disease activity and progression using a combination of endoscopy, laboratory markers, and imaging including FAI.
Recognize limitations of repeated endoscopy and consider FAI as a noninvasive adjunct for ongoing assessment.
Risks
Invasive procedures like colonoscopy have low utilization due to patient reluctance and preparation burden.
Traditional biomarkers (CRP, ESR, FC) are not definitive targets for tight control strategies.
Patient & Prescribing Data
Adults with confirmed IBD undergoing imaging and clinical follow-up
FAI may help identify patients who require intensive therapeutic strategies to control inflammation early and improve long-term outcomes.
Clinical Best Practices
Incorporate peri-bowel FAI measurement from routine abdominal CT scans to enhance risk stratification in IBD.
Use a multidisciplinary approach combining clinical, endoscopic, laboratory, and imaging data for comprehensive disease management.
Ensure standardized CT imaging protocols and target the most severe bowel lesion for FAI assessment.
